UNITED STATES SECURITIES AND EXCHANGE COMMISSION May 4, 2022

ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934

Acadia Pharmaceuticals, Inc.

File No. 0-50768 - CF#37253

Acadia Pharmaceuticals, Inc. submitted an application under Rule 24b-2 requesting extension of a previous grant of confidential treatment for information it excluded from the Exhibits to a Form 10-K filed on February 27, 2019.

Based on representations by Acadia Pharmaceuticals, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:

Exhibit 10.26	through February 27, 2025
Exhibit 10.27	through February 27, 2025

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Robert Errett Chief, Disclosure Management Office